DLL3 and small cell lung carcinoma: Tarlatamab, a bispecific T‐cell engager (BiTE) antibody that redirects T‐cells to target delta‐like ligand 3 (DLL3) on SCLC cells, has shown promising efficacy in the previously treated patients with SCLC [1].